Invesco
KERX

Invesco’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Invesco’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-23,263
Closed -$143K – 3744
2017
Q1 		$143K Buy
23,263
+2,718
+13% +$14.9K ﹤0.01% 3641
2016
Q4 		$120K Sell
20,545
-207,945
-91% -$1.14M ﹤0.01% 3602
2016
Q3 		$1.21M Buy
228,490
+209,036
+1,075% +$1.13M ﹤0.01% 2861
2016
Q2 		$129K Buy
+19,454
New +$109K ﹤0.01% 3612
2015
Q4 		– Sell
-933,215
Closed -$3.29M – 3779
2015
Q3 		$3.29M Sell
933,215
-576,589
-38% -$3.86M ﹤0.01% 2166
2015
Q2 		$15.1M Buy
1,509,804
+561,622
+59% +$6.02M 0.01% 1339
2015
Q1 		$12.1M Hold
948,182
– – ﹤0.01% 1457
2014
Q4 		$13.4M Hold
948,182
– – 0.01% 1395
2014
Q3 		$13M Hold
948,182
– – 0.01% 1393
2014
Q2 		$14.6M Sell
948,182
-706,261
-43% -$10M 0.01% 1374
2014
Q1 		$28.2M Buy
1,654,443
+234,496
+17% +$3.54M 0.01% 1058
2013
Q4 		$18.4M Buy
1,419,947
+254,535
+22% +$3.04M 0.01% 1226
2013
Q3 		$11.8M Buy
1,165,412
+290,051
+33% +$2.58M 0.01% 1390
2013
Q2 		$6.54M Buy
+875,361
New +$6.84M ﹤0.01% 1675

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Invesco's KERX Position: Q2 2017 in Review

Invesco sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2017, closing a stake of 23,263 shares — an estimated $143K sold.

Invesco first reported a position in KERX in Q2 2013 and held it in 14 quarters. The position peaked at $28.2M in Q1 2014. 126 funds tracked by Wall St. Rank hold KERX as of Q2 2017.

  • Invesco reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Invesco sold 23,263 Keryx Biopharmaceuticals Inc shares in Q2 2017, an estimated $143K.
  • Invesco first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 14 quarters.
  • Invesco's Keryx Biopharmaceuticals Inc position peaked at $28.2M in Q1 2014.
  • 126 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2017.

Based on Invesco's 13F filing for Q2 2017, filed 14 Aug 2017.